The top after-market NASDAQ gainers on Thursday were Procera Networks, Blucora Inc, FormFactor Inc, Anika Therapeutics Inc, and Immersion Corporation. The top after-market NASDAQ losers were ZAGG Inc, Arena Pharmaceuticals, Guidance Software Inc and Bruker Corporation.
Procera Networks Inc. (NASDAQ:PKT) shares climbed 21.84 percent to $13.50 in post-market trading. The company on Thursday reported a first quarter loss of $6.1 million, or 30 cents per share, for the quarter that ended March 31 but revenues improved 15 percent to $14.2 million and topped analysts’ estimate of $13.3 million. The company reported annual revenue growth at the high end of previously forecast range. Separately, Procera announced that it bagged a multi-million dollar order from clients in North America and Europe.
Blucora Inc. (NASDAQ:BCOR) shares climbed 13.57 percent to $16.66 in post-market trading. Blucora announced on Thursday its first quarter results that were above analysts' estimate. The company also provided a positive outlook for its second quarter. The company reported non-GAAP EPS of $0.95 and GAAP EPS of $0.53 versus the analysts' estimate of $0.50. Revenues for the quarter came in at $165.3 million versus the consensus estimate of $158.81 million. Blucora expects second quarter EPS to be in the range of $0.51-$0.55, versus the consensus estimate of $0.61.
FormFactor Inc. (NASDAQ:FORM) shares surged 7.14 percent to $5.10 in post-market trading after losing more than 4 percent in regular trading on Thursday. Equities researchers at Needham & Company increased their target price on shares of FormFactor from $7.00 to $8.00 in a report issued on Thursday, according to a StockRatingsNetwork report.
Anika Therapeutics Inc. (NASDAQ:ANIK) shares gained 5.26 percent to $13.80 in post-market trading. The company has a 52-week low of $9.13, a 52-week high of $17.70 and $182.48 million in market capitalization.
Immersion Corporation (NASDAQ:IMMR) shares advanced 4.69 percent to $11.60 in post-market trading after gaining more than 7 percent in regular trading on Thursday. The company on Thursday reported financial results for the first quarter. Total revenues for the first quarter of 2013 were $13.9 million, an increase of 43 percent in comparison to $9.7 million for the same quarter a year ago and Immersion’s highest total ever for a quarter. Net income for the first quarter of 2013 was $2.3 million, or $0.08 per share in comparison to a net loss of $219,000, or $0.01 per share, for the first quarter of 2012.
ZAGG Inc. (NASDAQ: ZAGG) shares tumbled 24.56 percent to $5.19 in post-market trading. The company reported first quarter earnings per share of $0.11, $0.10 worse than the analysts' estimate of $0.21. Revenues for the quarter came in at $51.5 million versus the consensus estimate of $66.57 million. Zagg Inc. slashed its FY2013 revenue forecast to a range of $274 million - $280 million, from its previous guidance of $313 million - $318 million and a consensus estimate of $315.8 million.
Guidance Software Inc. (NASDAQ:GUID) shares slumped 20.16 percent to $8.00 in post-market trading. The company reported first quarter loss per share of $0.15, $0.12 worse than the analysts' estimate of a loss of $0.03. Revenues for the quarter came in at $26.9 million versus the consensus estimate of $30.2 million. Guidance Software Inc. sees FY2013 earnings per share of ($0.20 - $0.00), versus a consensus estimate of $0.30. Guidance Software Inc. expects FY2013 revenues to be in the range of $133 million - $138 million, versus the consensus estimate of $146.06 million.
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) shares declined 17.73 percent to $6.91 in post-market trading. The company said that it has notified the European Medicines Agency that the company is withdrawing the BELVIQ Marketing Authorization Application (MAA) in the European Union. Currently, Arena is evaluating the best approach for submitting the application at a later date.
Bruker Corporation (NASDAQ:BRKR) shares fell 9.33 percent to $15.75 in post-market trading. The company updated fiscal 2013 guidance slashing its full-year 2013 adjusted per share guidance by $0.08 to a range of $0.80 to $0.83, while revenues growth rates are anticipated to fall by 2 percent.